Matthew Windrow, MD
Family Medicine · Hondo, TXNPI 1487673935
Payments from drug & device makers
Across 592 payments — averaging $203.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$116K
- AbbVie$1K
- Novo Nordisk$649
- AstraZeneca$548
- Merck$330
- Lilly USA, LLC$216
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$115,60096%
- Food & beverage$4,6674%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical | 287 | $115,633 |
| AbbVie(2 entities) | 101 | $1,243 |
| Novo Nordisk | 44 | $649 |
| AstraZeneca | 26 | $548 |
| Merck | 23 | $330 |
| Lilly USA, LLC | 13 | $216 |
| Otsuka America Pharmaceutical, Inc. | 11 | $172 |
| Averitas Pharma Inc. | 9 | $153 |
| GSK | 5 | $127 |
| Supernus Pharmaceuticals, Inc. | 8 | $118 |
| Teva Pharmaceuticals USA, Inc. | 6 | $117 |
| Amgen | 7 | $115 |
| Pfizer | 5 | $91 |
| Novartis | 5 | $77 |
| Astellas Pharma US Inc | 5 | $76 |
| Johnson & Johnson | 4 | $49 |
| Ironshore Pharmaceuticals Inc. | 3 | $49 |
| Exact Sciences | 3 | $48 |
| Lundbeck LLC | 3 | $45 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Biogen | 2 | $39 |
| Bayer | 2 | $35 |
| Genentech USA, Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Dexcom, Inc. | 1 | $27 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| SK Life Science, Inc. | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Corium, LLC | 1 | $18 |
| Organon | 1 | $16 |
| Promius Pharma LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Allografts$95,300
- ALLOCATE$20,300
How this compares
$120,267 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 171 | $164,867 |
| MounjaroTirzepatide | 135 | $152,695 |
| EliquisApixaban | 225 | $137,927 |
| JanuviaSitagliptin Phosphate | 116 | $108,790 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $101,026 |
| JardianceEmpagliflozin | 57 | $51,729 |
| XareltoRivaroxaban | 40 | $39,797 |
| RybelsusSemaglutide | 25 | $33,350 |
| TrulicityDulaglutide | 27 | $24,855 |
| TradjentaLinagliptin | 15 | $16,402 |
| MyrbetriqMirabegron | 34 | $16,041 |
| FarxigaDapagliflozin Propanediol | 17 | $14,157 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $12,110 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $11,645 |
| Gabapentin | 549 | $9,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $649 | $198,217196 claims |
| Lilly USA, LLCMounjaro, Trulicity | $216 | $177,550162 claims |
| PfizerEliquis, Premarin | $91 | $143,750236 claims |
| MerckJanuvia, Janumet Xr | $330 | $116,336128 claims |
| GSKTrelegy Ellipta | $127 | $101,026137 claims |
| Johnson & JohnsonXarelto | $49 | $39,79740 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $548 | $25,74348 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $16,04134 claims |
| NovartisEntresto | $77 | $8,69117 claims |
| AbbVieLinzess | $1,243 | $6,32712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Hondo
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.